A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Check out the companies making headlines after the bell:
Tesla shares rose 1 percent in after-hours trading after investment firm Macquarie gave the automaker an 'outperform' rating and a price target of $430. Tesla shares closed at $250.56 on Monday.
Edwards Lifesciences stock rose 1 percent in the extended session after announcing the start of an 1,000-patient clinical trial to study its transcatheter valve technology. The device is intended for patients at high risk of open-heart surgery.
Affimed shares plunged more than 23 percent in after-hours trading following news that the company is suspending the clinical study of its AFM11 cancer drug after one patient died during the phase 1 study. Two other patients suffered from "life-threatening events," the company said in a statement. All three patients were taking the highest dosage of AFM11 during the study.